Dr. Perez Discusses the BOLERO-2 Everolimus Trial

Edith A. Perez, MD
Published: Wednesday, Dec 14, 2011

Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses the results of the phase III BOLERO-2 trial that examined women with hormone receptor-positive (HR+) metastatic breast cancer that had developed disease progression and resistance to aromatase inhibitors.

The trial enrolled 724 postmenopausal women that had progressed on anastrozole or letrozole. Patients were randomized 2:1 to receive exemestane plus everolimus or exemestane and placebo. The addition of everolimus resulted in a median progression-free survival of 7.4 months compared to 3.2 months in the control arm.

Perez describes the results of the BOLERO-2 trial as unprecedented. The addition of everolimus showed clinical efficacy and offers immense value for patients with refractory estrogen receptor positive metastatic breast cancer.

Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses the results of the phase III BOLERO-2 trial that examined women with hormone receptor-positive (HR+) metastatic breast cancer that had developed disease progression and resistance to aromatase inhibitors.

The trial enrolled 724 postmenopausal women that had progressed on anastrozole or letrozole. Patients were randomized 2:1 to receive exemestane plus everolimus or exemestane and placebo. The addition of everolimus resulted in a median progression-free survival of 7.4 months compared to 3.2 months in the control arm.

Perez describes the results of the BOLERO-2 trial as unprecedented. The addition of everolimus showed clinical efficacy and offers immense value for patients with refractory estrogen receptor positive metastatic breast cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x